Loading…
Please register to continue your trial period!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Antibody-Drug-Conjugates (ADCs) & Bladder Cancer, in December 2019, the US Food and Drug Administration granted accelerated approval to enfortumab vedotin, a novel nectin-4-targeting antibody-drug conjugate. This approval was specifically for the treatment of platinum-refractory and immune checkpoint blockade-refractory locally advanced or metastatic Bladder Cancer. Antibody-Drug-Conjugates (ADCs) represent an emerging therapeutic approach in the treatment of Bladder Cancer. Beyond nectin-4, there are ongoing clinical development…